Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood and urine may hold clues to rare breathing condition

NCT ID NCT06997146

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to find biological markers in blood and urine that could explain congenital central hypoventilation syndrome (CCHS), a rare disorder where the brain fails to control breathing during sleep. Researchers will collect samples from 40 adults with CCHS and healthy volunteers during sleep and wakefulness. The goal is to identify disrupted pathways and potential targets for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood and urine sampling for biomarker analysis
What this could lead to
If successful, this could identify biological markers that help diagnose or predict CCHS progression, and reveal new targets for future treatments.
What could go wrong
This is an early-stage observational study with only 40 participants, so findings may not apply to all CCHS patients. It does not test any treatment directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: CCHS patients : 1. Age 18 years old or older; 2. Carry a polyA expansion mutation in PHOX2B; 3. Receive nocturnal mechanical ventilation; 4. Patients that are under the care and treatment in the CCHS center: Hôpital Universitaire Pitié-Salpêtrière 5. Written informed consent from the patient 6. Affiliated to The French social security except patient on AME (state medical aid) Control group : 1. Age 18 years old or older. 2. Healthy with no major medical illnesses in the past year (such as diabetes, cancer, pregnancy, lungs disease). 3. Matched for sex, age (+/- 3 years), origin and BMI category with a CCHS patient 4. Written informed consent of the control 5. Affiliated to The French social security except patient on AME (state medical aid) Exclusion Criteria: CCHS patients : 1. Age lower than 18 years old; 2. Pregnancy or breastfeeding 3. Patients with diaphragmatic (phrenic nerve) pacing; 4. Patients with late onset CCHS; 5. Patients that were diagnosed with a major medical illnesses/condition other than CCHS in the past year (such as diabetes, cancer, lungs disease, a sleep disorder, or pregnancy) 6. Patients that suffer from a sleep disorder such as insomnia, restless legs syndrome, nightmares 7. Patients who use medications that are likely to impair sleep structure 8. Individuals under guardianship, or permanently legally incompetent adults, under judicial protection, deprived of liberty, patients unable to express their consent. Control group : 1. Age lower than 18 years old; 2. Pregnancy or breastfeeding 3. Controls that were diagnosed with a major medical illnesses/condition in the past year (such as diabetes, cancer, lungs disease, a sleep disorder, or pregnancy) 4. Controls that suffer from a sleep disorder such as insomnia, restless legs syndrome, nightmares 5. Controls who use medications that are likely to impair sleep structure. 6. Individuals under guardianship, or permanently legally incompetent adults, under judicial protection, deprived of liberty, patients unable to express their consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congenital central hypoventilation syndrome (CCHS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pitié-Salpêtrière Hospital

    Paris, 75013, France